These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 32694034)
21. Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease. B B; A R; G R; A N; D G; S G; P F; M SG; L C; B G J Cyst Fibros; 2021 Sep; 20(5):768-771. PubMed ID: 34162524 [No Abstract] [Full Text] [Related]
22. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease. Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351 [TBL] [Abstract][Full Text] [Related]
23. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization? Terlizzi V J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487 [No Abstract] [Full Text] [Related]
24. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Burgel PR; Durieu I; Chiron R; Ramel S; Danner-Boucher I; Prevotat A; Grenet D; Marguet C; Reynaud-Gaubert M; Macey J; Mely L; Fanton A; Quetant S; Lemonnier L; Paillasseur JL; Da Silva J; Martin C; Am J Respir Crit Care Med; 2021 Jul; 204(1):64-73. PubMed ID: 33600738 [No Abstract] [Full Text] [Related]
25. Dual and triple modulator therapy for chronic rhinosinusitis in cystic fibrosis patients. Uyttebroek S; Claeyssens C; Jorissen M; Dupont L; Van Gerven L Rhinology; 2024 Aug; 62(4):457-465. PubMed ID: 38530204 [TBL] [Abstract][Full Text] [Related]
26. Year in review 2023 - Back to the future. Cristiani L; Fernandes FF J Cyst Fibros; 2024 Mar; 23(2):203-207. PubMed ID: 38431442 [TBL] [Abstract][Full Text] [Related]
27. The march towards CFTR modulator access for all people with CF: The end of the beginning. VanDevanter DR J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080 [No Abstract] [Full Text] [Related]
28. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn? Edmondson C; Course CW; Doull I Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533 [TBL] [Abstract][Full Text] [Related]
34. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis. Middleton PG; Taylor-Cousar JL Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928 [No Abstract] [Full Text] [Related]
35. Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis. DiMango E; Spielman DB; Overdevest J; Keating C; Francis SF; Dansky D; Gudis DA Int Forum Allergy Rhinol; 2021 Jan; 11(1):75-78. PubMed ID: 32985756 [TBL] [Abstract][Full Text] [Related]
36. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis. Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870 [TBL] [Abstract][Full Text] [Related]